Syneos Health and Aetion Partner to Offer RWE Solutions to Advance Drug Development and Commercialization
MORRISVILLE, N.C. and NEW YORK, Aug. 2, 2021 /PRNewswire/ -- Syneos Health® (Nasdaq:SYNH) and Aetion® announced a partnership to provide regulatory-grade data and analytics-driven solutions to advance drug development and improve patient outcomes.
- The partnership brings together Syneos Health's proprietary data collection and research solutions with Aetion Evidence Platform (AEP) to generate evidence through patient data curation and real-world data.
- "Integrating Syneos Health and Aetion's solutions drives quality, transparency, and speed in the use of patient-level data by leveraging Aetion's strong analytics platform and capabilities.
- "Aetion is becoming the partner of choice for organizations committed to the highest standards of scientific rigor for creating RWE," said Carolyn Magill, CEO of Aetion.
- In 2020, Aetion became the first RWE company to establish an FDA COVID-19 research collaboration agreement and was selected by ICER as its preferred RWE partner and platform.